Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Filings indexed 572 across all filing types
Latest filing 2025-11-28 Proxy Solicitation & In…
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
SoftOx Solutions AS: Notice of Extraordinary General Assembly - Attachment: Softox Solutions AS Call EGA 15.12.25.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' for Softox Solutions AS. It includes the agenda, proposed resolutions (specifically regarding the issuance of subscription rights), and proxy/attendance forms for shareholders. This document is designed to provide information to shareholders and solicit their votes for an upcoming meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2025-11-28 English
SoftOx Solutions AS: Notice of Extraordinary General Assembly
AGM Information Classification · 95% confidence The document is a short announcement (1135 characters) notifying shareholders of an upcoming Extraordinary General Meeting. It explicitly states that the notice and agenda are 'enclosed with this notification' and provides a link to the documents. Per the 'Menu vs Meal' rule, this is an announcement regarding the publication of meeting materials rather than the proxy statement or the meeting presentation itself, making it a Report Publication Announcement (RPA).
2025-11-28 English
SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited
Capital/Financing Update Classification · 100% confidence The document announces a private placement of shares and the exercise of a financing facility by SoftOx Solutions AS. It details the subscription price, the number of shares issued, and the resulting change in share capital. This falls under the category of capital raising and financing activities, specifically involving the issuance of new shares to secure funding.
2025-11-28 English
SoftOx Solutions AS: Third Quarter Report 2025 - Attachment: SoftOx Solutions_Q3 Report_2025.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'SoftOx Solutions Group Financial Report Q3 2025'. It contains comprehensive financial statements, including a table of key figures for the third quarter and the first three quarters of 2025, alongside detailed management commentary on clinical development, strategy, and funding activities. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2025
2025-11-26 English
SoftOx Solutions AS: Third Quarter Report 2025
Report Publication Announcement Classification · 100% confidence The document is extremely short (175 characters) and explicitly states 'Please find attached the Third Quarter Report 2025'. According to the 'Menu vs Meal' rule, an announcement stating that a report is attached or available is classified as a Report Publication Announcement (RPA), rather than the report itself.
2025-11-26 English
SoftOx Solutions AS: GMP Drug Substance Successfully Manufactured – Key Milestone for CF and EDF Clinical Programs
Regulatory Filings Classification · 100% confidence The document is a corporate press release announcing a technical milestone (GMP manufacturing of a drug substance) for the company's clinical programs. It does not contain financial statements, dividend declarations, or regulatory filings of a specific form type. As it is a general corporate announcement regarding operational progress, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2025-11-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.